Navigation Links
Neogen Announces 3 for-2 Stock Split
Date:11/16/2009

LANSING, Mich., Nov. 16 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) today announced that its Board of Directors has approved a 3-for-2 stock split. With the split, shareholders of record on Nov. 30, 2009, will receive one additional share of stock for each two shares held.

The stock split will be effected in the form of a stock dividend that will be paid in newly issued common stock on Dec. 15, 2009. As of today, Neogen has approximately 15,000,000 shares of common stock outstanding. After the stock split, the company will have approximately 22,500,000 shares of common stock outstanding. This is the third stock dividend declared by the company. The most recent was a 3-for-2 split in September 2007.

"We are very pleased to be able to enhance the availability and liquidity of our shares to allow more participation in Neogen's success, while at the same time rewarding our large number of loyal long-term investors," said James Herbert, Neogen's chief executive officer and chairman. "This stock split reflects our Board's strong belief in Neogen's long-term growth, and recognizes a doubling of our stock price during the past year."

All fractional shares resulting from the dividend will be exchanged for cash at the fair market value of Neogen's common stock based on the closing sales price per share on Nov. 30, 2009, as reported on the NASDAQ National Market System.

Stockholders contemplating a transaction of Neogen stock between the record date and payment date should consult a broker regarding entitlement to the dividend shares.

Neogen Corporation develops and markets products dedicated to food and animal safety. The Company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food a
'/>"/>

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neogen to Ring NASDAQs Closing Bell
2. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
3. Neogen Again Named to Forbes List of Best Small Companies
4. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
5. NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009
6. NeoGenomics Reports Second Quarter 2009 Results
7. Neogen Reports 16% Increase in Revenues
8. Neogen Corporation Announces Year-End Results Conference Call
9. Neogen Named to Fortunes List of Fastest Growing Companies
10. Neogen Named to Fortunes List of 40 Stocks To Retire On
11. Neogen Partners With Chinese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... that it has commenced a public offering of ... shares of its common stock and overallotment purchase ... The shares of common stock, warrants and overallotment ...
(Date:5/27/2015)... DUBLIN , May 26, 2015 ... addition of the "Global Breast Cancer Monoclonal ... offering. Globally, Roche seems to dominate ... largest inventory. Its block buster molecule, Herceptin has ... years. It was found that breast cancer cells ...
(Date:5/27/2015)... Expanding in a big way into ... Biomed Inc. recently inked a deal with Arthur ... Ltd. , the largest endodontic distributor in Japan. The ... for Avalon Biomed, which manufactures Grey MTA Plus® and ... cements that have won renown from dentists around the ...
(Date:5/27/2015)... 27, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... 2015. Aviv Boim , CEO ... work to generate functional specific antibodies, targeting identified cancer ... are encouraged by the development progress. We are excited ... which modulate immune checkpoints gain clinical acceptance for cancer ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
... BOZEN, Italy, December 29 Health Robotics ... agreement with the Devon International Group,(DIG), whereby ... Health Robotics,CytoCare(TM) and i.v.STATION(TM) robots in the ... unique benefits with great appeal to,Government and ...
... 29 AlloSource, one of the nation,s largest non-profit ... use in surgical procedures, will this year sponsor one ... Life float in the January 1 Tournament of Roses ... a tribute to the millions of people touched by ...
... Prescription Product Increases Length, Thickness and Darkness of EyelashesIRVINE, ... AGN ) today announced the U.S. Food and Drug ... as a novel treatment for hypotrichosis of the eyelashes. ... or not enough eyelashes. LATISSE(TM) is the first ...
Cached Biology Technology:Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 2Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 3Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 4AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 2AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 2Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 4Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 6Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 7Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 8Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 9
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... crystal ball. A new approach to predict whether a ... dose is best could get antibiotics to market faster ... In recent years, scientists worldwide have sounded the alarm: ... Bacteria are increasingly adept at outwitting the traditional antibiotic ...
... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
... been found by Health Canada and the U.S. Food ... or bottled foods. A new study by McGill researchers ... explains the presence of this chemical in a wide ... the October, 2004 issue of Journal of Agricultural and ...
Cached Biology News:New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: